Targeting inflammation in emerging therapies for genetic retinal disease

International Journal of Inflammation

Volumn 2013, Issue , 2013, Pages

  Viringipurampeer, Ishaq A ^a   Bashar, Abu E ^a   Gregory Evans, Cheryl Y ^a   Moritz, Orson L ^a   Gregory Evans, Kevin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; DEXAMETHASONE; ECULIZUMAB; FLUOCINOLONE ACETONIDE; GLATIRAMER; INFLIXIMAB; LIPOFUSCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FCFD4514S; RANIBIZUMAB; RAPAMYCIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLINDNESS; COMPLEMENT SYSTEM; DEVELOPING COUNTRY; DRUG EFFICACY; GENETIC DISORDER; GENETIC RETINA DISEASE; HUMAN; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; SUBRETINAL NEOVASCULARIZATION;

EID: 84876511182     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2013/581751     Document Type: Review

References (84)

1. Pascolini D., Mariotti S. P., Global estimates of visual impairment 2010. British Journal of Ophthalmology 2010 96 5 614 618 10.1136/bjophthalmol-2011- 300539
2. Resnikoff S., Pascolini D., Etya'ale D., Kocur I., Pararajasegaram R., Pokharel G. P., Mariotti S. P., Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 2004 82 11 844 851 2-s2.0-9644283089 (Pubitemid 39573742)
3. Wright A. F., Chakarova C. F., Abd El-Aziz M. M., Bhattacharya S. S., Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nature Reviews Genetics 2010 11 4 273 284 2-s2.0-77949773491 10.1038/nrg2717
4. Tomany S. C., Wang J. J., Van Leeuwen R., Klein R., Mitchell P., Vingerling J. R., Klein B. E. K., Smith W., De Jong P. T. V. M., Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004 111 7 1280 1287 2-s2.0-3042662037 10.1016/j.ophtha.2003.11.010 (Pubitemid 38844822)
5. Tan J. S. L., Wang J. J., Flood V., Rochtchina E., Smith W., Mitchell P., Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008 115 2 334 341 2-s2.0-38749097003 10.1016/j.ophtha.2007.03.083 (Pubitemid 351175680)
6. Plafker S. M., O'Mealey G. B., Szweda L. I., Mechanisms for countering oxidative stress and damage in retinal pigment epithelium. International Review of Cell and Molecular Biology 2012 298 135 177
7. Boyer N. P., Higbee D., Currin M. B., Blakeley L. R., Chen C., Ablonczy Z., Crouch R. K., Koutalos Y., Lipofuscin and N -retinylidene- N -retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal. Journal of Biological Chemistry 2012 287 26 22276 22286
8. Booij J. C., Baas D. C., Beisekeeva J., Gorgels T. G. M. F., Bergen A. A. B., The dynamic nature of Bruch's membrane. Progress in Retinal and Eye Research 2010 29 1 1 18 2-s2.0-74749083052 10.1016/j.preteyeres.2009.08.003
9. Swaroop A., Chew E. Y., Rickman C. B., Abecasis G. R., Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annual Review of Genomics and Human Genetics 2009 10 19 43 2-s2.0-70350238360 10.1146/annurev.genom.9.081307. 164350
10. Lim L. S., Mitchell P., Seddon J. M., Holz F. G., Wong T. Y., Age-related macular degeneration. The Lancet 2012 379 9827 1728 1738
11. Doonan F., Groeger G., Cotter T. G., Preventing retinal apoptosis-is there a common therapeutic theme? Experimental Cell Research 2012 318 11 1278 1284
12. Gehrs K. M., Anderson D. H., Johnson L. V., Hageman G. S., Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Annals of Medicine 2006 38 7 450 471 2-s2.0-33751103471 10.1080/07853890600946724 (Pubitemid 44767496)
13. Yoshida N., Ikeda Y., Notomi S., Ishikawa K., Murakami Y., Hisatomi T., Enaida H., Ishibashi T., Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2013 120 1 100 105 10.1016/j.ophtha.2012.07.006
14. Penfold P. L., Provis J. M., Furby J. H., Gatenby P. A., Billson F. A., Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 1990 228 3 270 274 2-s2.0-0025321591 10.1007/BF00920033 (Pubitemid 20150313)
15. Gurne D. H., Tso M. O. M., Edward D. P., Ripps H., Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology 1991 98 5 602 607 2-s2.0-0025736918
16. Killingsworth M. C., Sarks J. P., Sarks S. H., Macrophages related to Bruch's membrane in age-related macular degeneration. Eye 1990 4 4 613 621 2-s2.0-0025086052 (Pubitemid 20376823)
17. Mullins R. F., Russell S. R., Anderson D. H., Hageman G. S., Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB Journal 2000 14 7 835 846 2-s2.0-0034012166 (Pubitemid 30241660)
18. Hageman G. S., Luthert P. J., Chong N. H. V., Johnson L. V., Anderson D. H., Mullins R. F., An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Progress in Retinal and Eye Research 2001 20 6 705 732 2-s2.0-0034832029 10.1016/S1350-9462(01)00010-6 (Pubitemid 32918285)
19. Goverdhan S. V., Khakoo S. I., Gaston H., Chen X., Lotery A. J., Age-related macular degeneration is associated with the HLA-cw * 0701 genotype and the natural killer cell receptor AA haplotype. Investigative Ophthalmology and Visual Science 2008 49 11 5077 5082 2-s2.0-56149112376 10.1167/iovs.08-1837
20. Crabb J. W., Miyagi M., Gu X., Shadrach K., West K. A., Sakaguchi H., Kamei M., Hasan A., Yan L., Rayborn M. E., Salomon R. G., Hollyfield J. G., Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2002 99 23 14682 14687 2-s2.0-11144258543 10.1073/pnas. 222551899 (Pubitemid 35334544)
21. Bhutto I., Lutty G., Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Molecular Aspects of Medicine 2012 33 4 295 317
22. Detrick B., Hooks J. J., Immune regulation in the retina. Immunologic Research 2010 47 1-3 153 161 2-s2.0-77953962770 10.1007/s12026-009-8146-1
23. Sparrrow J. R., Hicks D., Hamel C. P., The retinal pigment epithelium in health and disease. Current Molecular Medicine 2010 10 9 802 823 2-s2.0-78651299482 10.2174/156652410793937813
24. Klein R. J., Zeiss C., Chew E. Y., Tsai J. Y., Sackler R. S., Haynes C., Henning A. K., SanGiovanni J. P., Mane S. M., Mayne S. T., Bracken M. B., Ferris F. L., Ott J., Barnstable C., Hoh J., Complement factor H polymorphism in age-related macular degeneration. Science 2005 308 5720 385 389 2-s2.0-20244380171 10.1126/science.1109557 (Pubitemid 40530070)
25. Haines J. L., Hauser M. A., Schmidt S., Scott W. K., Olson L. M., Gallins P., Spencer K. L., Shu Y. K., Noureddine M., Gilbert J. R., Schnetz-Boutaud N., Agarwal A., Postel E. A., Pericak-Vance M. A., Complement factor H variant increases the risk of age-related macular degeneration. Science 2005 308 5720 419 421 2-s2.0-20244388812 10.1126/science.1110359 (Pubitemid 40530081)
26. Edwards A. O., Ritter R. III, Abel K. J., Manning A., Panhuysen C., Farrer L. A., Complement factor H polymorphism and age-related macular degeneration. Science 2005 308 5720 421 424 2-s2.0-17244379811 10.1126/science.1110189 (Pubitemid 40530082)
27. Gold B., Merriam J. E., Zernant J., Hancox L. S., Taiber A. J., Gehrs K., Cramer K., Neel J., Bergeron J., Barile G. R., Smith R. T., Hageman G. S., Dean M., Allikmets R., Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nature Genetics 2006 38 4 458 462 2-s2.0-33645419787 10.1038/ng1750
28. Hughes A. E., Orr N., Esfandiary H., Diaz-Torres M., Goodship T., Chakravarthy U., A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nature Genetics 2006 38 10 1173 1177 2-s2.0-33749123246 10.1038/ng1890 (Pubitemid 44470363)
29. Chen Y., Bedell M., Zhang K., Age-related macular degeneration: genetic and environmental factors of disease. Molecular Interventions 2010 10 5 271 281 2-s2.0-78149475685 10.1124/mi.10.5.4
30. Newman A. M., Gallo N. B., Hancox L. S., Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks? Genome Medicine 2012 4 2 16 10.1186/gm315
31. Doyle S. L., Campbell M., Ozaki E E., NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nature Medicine 2012 18 5 791 798 10.1038/nm.2717
32. Tarallo V., Hirano Y., Gelfand B. D., DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 2012 149 4 847 859 10.1016/j.cell.2012.03.036
33. Kaneko H., Dridi S., Tarallo V., Gelfand B. D., Fowler B. J., Cho W. G., Kleinman M. E., Ponicsan S. L., Hauswirth W. W., Chiodo V. A., Karikó K., Yoo J. W., Lee D. K., Hadziahmetovic M., Song Y., Misra S., Chaudhuri G., Buaas F. W., Braun R. E., Hinton D. R., Zhang Q., Grossniklaus H. E., Provis J. M., Madigan M. C., Milam A. H., Justice N. L., Albuquerque R. J. C., Blandford A. D., Bogdanovich S., Hirano Y., Witta J., Fuchs E., Littman D. R., Ambati B. K., Rudin C. M., Chong M. M. W., Provost P., Kugel J. F., Goodrich J. A., Dunaief J. L., Baffi J. Z., Ambati J., DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 2011 471 7338 325 332 2-s2.0-79952786337 10.1038/nature09830
34. Dinarello C. A., Interleukin-1 β interleukin-18, and the interleukin-1 β converting enzyme. Annals of the New York Academy of Sciences 1998 856 1 11 2-s2.0-0031739525
35. Martinon F., Burns K., Tschopp J., The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL- β Molecular Cell 2002 10 2 417 426 2-s2.0-0036671894 10.1016/S1097-2765(02)00599-3 (Pubitemid 35007355)
36. Akira S., Uematsu S., Takeuchi O., Pathogen recognition and innate immunity. Cell 2006 124 4 783 801 2-s2.0-32944464648 10.1016/j.cell.2006.02.015 (Pubitemid 43261452)
37. Boyden E. D., Dietrich W. F., Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nature Genetics 2006 38 2 240 244 2-s2.0-31744441475 10.1038/ng1724 (Pubitemid 43177241)
38. Zhao Y., Yang J J., Shi J., The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011 477 7366 596 600 10.1038/nature10510
39. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006 440 7081 237 241 2-s2.0-32944468985 10.1038/nature04516 (Pubitemid 43372104)
40. Fernandes-Alnemri T., Yu J. W., Datta P., Wu J., Alnemri E. S., AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009 458 7237 509 513 2-s2.0-63649145255 10.1038/nature07710
41. Jones L. L., Vignali D. A., Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunology Research 2011 52 5 14
42. Tanaka T., Narazaki M., Kishimoto T., Therapeutic targeting of the interleukin-6 receptor. Annual Reviews in Pharmacologic Toxicolgy 2012 52 199 219
43. Miao H., Tao Y., Li X. X., Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization. Molecular Vision 2012 18 574 580
44. Fessel W. J., Serum protein disturbance in retinitis pigmentosa. And the association of retinitis pigmentosa with psychosis. American Journal of Ophthalmology 1962 53 4 640 642 2-s2.0-0345335117
45. Rahi A. H., Autoimmunity and the retina. I. Antigenic specificity of photoreceptor cells. British Journal of Ophthalmology 1970 54 7 441 444 2-s2.0-0014823329
46. Rahi A. H., Autoimmunity and the retina. II. Raised serum IgM levels in retinitis pigmentosa. British Journal of Ophthalmology 1973 57 12 904 909 2-s2.0-0015871444
47. Spalton D. J., Rahi A. H. S., Bird A. C., Immunological studies in retinitis pigmentosa associated with retinal vascular leakage. British Journal of Ophthalmology 1978 62 3 183 187 2-s2.0-0017862023 (Pubitemid 8314475)
48. Wong V. G., Green W. R., Kuwabara T., McMaster P. R., Cameron T. P., Homologous retinal outer segment immunization in primates: a clinical and histopathological study. Transactions of the American Ophthalmological Society 1974 72 184 195 2-s2.0-0016134911
49. Brinkman C. J. J., Pinckers A. J. L. G., Broekhuyse R. M., Immune reactivity to different retinal antigens in patients suffering from retinitis pigmentosa. Investigative Ophthalmology and Visual Science 1980 19 7 743 750 2-s2.0-0019252230 (Pubitemid 11078448)
50. Heredia C. D., Huguet J., Cols N., Engel P., Garcia-Calderon P. A., Immune complexes in retinitis pigmentosa. British Journal of Ophthalmology 1984 68 11 811 814 2-s2.0-0021735763 (Pubitemid 15146083)
51. Detrick B., Rodrigues M., Chan C. C., Tso M. O., Hooks J. J., Expression of HLA-DR antigen on retinal pigment epithelial cells in retinitis pigmentosa. American Journal of Ophthalmology 1986 101 5 584 590 2-s2.0-0022623288 (Pubitemid 16114205)
52. Newsome D. A., Michels R. G., Detection of lymphocytes in the vitreous gel of patients with retinitis pigmentosa. American Journal of Ophthalmology 1988 105 6 596 602 2-s2.0-0023920768
53. Gupta N., Brown K. E., Milam A. H., Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Experimental Eye Research 2003 76 4 463 471 2-s2.0-0037375042 10.1016/S0014-4835(02)00332-9 (Pubitemid 36299058)
54. Zeng H. Y., Zhu X. A., Zhang C., Yang L. P., Wu L. M., Tso M. O. M., Identification of sequential events and factors associated with microglial activation, migration, and cytotoxicity in retinal degeneration in rd mice. Investigative Ophthalmology and Visual Science 2005 46 8 2992 2999 2-s2.0-24644480719 10.1167/iovs.05-0118 (Pubitemid 43086724)
55. Yoshida N., Ikeda Y., Notomi S., Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2013 120 1 e5 e12 10.1016/j.ophtha.2012.07.008
56. Pearson R. A., Barber A. C., Rizzi M., Restoration of vision after transplantation of photoreceptors. Nature 2012 485 7396 99 103 10.1038/nature10997
57. Maguire A. M., High K. A., Auricchio A., Wright J. F., Pierce E. A., Testa F., Mingozzi F., Bennicelli J. L., Ying G. S., Rossi S., Fulton A., Marshall K. A., Banfi S., Chung D. C., Morgan J. I., Hauck B., Zelenaia O., Zhu X., Raffini L., Coppieters F., De Baere E., Shindler K. S., Volpe N. J., Surace E. M., Acerra C., Lyubarsky A., Redmond T. M., Stone E., Sun J., McDonnell J. W., Leroy B. P., Simonelli F., Bennett J., Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. The Lancet 2009 374 9701 1597 1605 2-s2.0-70350620424 10.1016/S0140-6736(09)61836-5
58. Kusnyerik A., Greppmaier U., Wilke R., Positioning of electronic subretinal implants in blind retinitis pigmentosa patients through multimodal assessment of retinal structures. Investigative Ophthalmology and Visual Science 2012 53 7 3748 3755 10.1167/iovs.11-9409
59. Trifunovic D., Sahaboglu A., Kaur J., Neuroprotective strategies for the treatment of inherited photoreceptor degeneration. Current Molecular Medicine 2012 12 5 598 612
60. Lally D. R., Gerstenblith A. T., Regillo C. D., Preferred therapies for neovascular age-related macular degeneration. Current Opinion in Ophthalmology 2012 23 3 182 188 10.1097/ICU.0b013e328352411c
61. Fletcher E. L., Jobling A. I., Vessey K. A., Luu C., Guymer R. H., Baird P. N., Animal models of retinal disease. Progress in Molecular Biology and Translational Science 2011 100 211 286
62. Pennesi M. E., Neuringer M., Courtney R. J., Animal models of age related macular degeneration. Molecular Aspects of Medicine 2012 33 4 487 509
63. Sallam A., Taylor S. R., Lightman S., Review and update of intraocular therapy in noninfectious uveitis. Current Opinion in Ophthalmology 2011 22 6 517 522
64. Yehoshua Z., Rosenfeld P. J., Albini T. A., Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Seminars in Ophthalmology 2011 26 3 167 180 2-s2.0-79957594942 10.3109/08820538.2011.577132
65. Ehmann D., García R., Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Canadian Journal of Ophthalmology 2010 45 1 36 40 2-s2.0-76149131060 10.3129/i09-243
66. Sivaprasad S., Patra S., Dacosta J., Adewoyin T., Shona O., Pearce E., Chong N. V., A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. Ophthalmologica 2011 225 4 200 206 2-s2.0-79551547437 10.1159/000322363
67. London N. J. S., Chiang A., Haller J. A., The dexamethasone drug delivery system: indications and evidence. Advances in Therapy 2011 28 5 351 366 2-s2.0-79958211809 10.1007/s12325-011-0019-z
68. Kupperman B., Safety and efficacy of dexamethasone intravitreal implant as adjunctive therapy to Lucentis in patients with choroidal neovascularization secondary to age-related macular degeneration. Proceedings of the 33rd Annual Macular Society Meeting February 2010 Tucson, Ariz, USA
69. Kane F. E., Burdan J., Cutino A., Green K. E., Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opinion on Drug Delivery 2008 5 9 1039 1046 2-s2.0-54049091605 10.1517/17425247.5.9.1039
70. Kolosova N. G., Muraleva N. A., Zhdankina A. A., Stefanova N. A., Fursova A. Z., Blagosklonny M. V., Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. American Journal of Pathology 2012 181 2 472 477
71. Landa G., Rosen R. B., Patel A., Lima V. C., Tai K. W., Perez V. R., Aizman A., Garcia P. M. T., Qualitative spectral OCT/SLO analysis of drusen change in dry age-related macular degeneration patients treated with copaxone. Journal of Ocular Pharmacology and Therapeutics 2011 27 1 77 82 2-s2.0-79951985780 10.1089/jop.2010.0109
72. Kadam R. S., Tyagi P., Edelhauser H. F., Kompella U. B., Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. International Journal of Pharmacology 2012 434 140 147
73. Olson J. L., Courtney R. J., Mandava N., Intravitreal infliximab and choroidal neovascularization in an animal model. Archives of Ophthalmology 2007 125 9 1221 1224 2-s2.0-34548653580 10.1001/archopht.125.9.1221 (Pubitemid 47403029)
74. Troutbeck R., Al-Qureshi S., Guymer R. H., Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clinical Experimental Ophthalmology 2012 40 1 18 26
75. Schnatbaum K., Locardi E., Scharn D., Richter U., Hawlisch H., Knolle J., Polakowski T., Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorganic and Medicinal Chemistry Letters 2006 16 19 5088 5092 2-s2.0-33747368498 10.1016/j.bmcl.2006.07.036 (Pubitemid 44247704)
76. Fridkis-Hareli M., Storek M., Mazsaroff I., Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011 118 17 4705 4713 10.1182/blood-2011-06-359646
77. Rohrer B., Long Q., Coughlin B., Brooks Wilson R., Huang Y., Qiao F., Tang P. H., Kunchithapautham K., Gilkeson G. S., Tomlinson S., A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Investigative Ophthalmology and Visual Science 2009 50 7 3056 3064 2-s2.0-67649989567 10.1167/iovs.08-2222
78. Ozdemir H., Karacorlu M., Karacorlu S., Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmologica Scandinavica 2005 83 2 248 251 2-s2.0-17644394246 10.1111/j.1600-0420.2005.00395.x (Pubitemid 40561839)
79. Srour M., Querques G., Leveziel N., Zerbib J., Tilleul J., Boulanger-Scemama E., Souied E. H., Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefe's Archive for Clinical and Experimental Ophthalmology 2012 10.1007/s00417-012-2249-4
80. Iezzi R., Guru B. R., Glybina I. V., Mishra M. K., Kennedy A., Kannan R. M., Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012 33 979 988
81. Zarbin M. A., Rosenfeld P. J., Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010 30 9 1350 1367 2-s2.0-77958524704 10.1097/IAE.0b013e3181f57e30
82. Xue W., Cojocaru R. I., Dudley V. J., Brooks M., Swaroop A., Sarthy V. P., Ciliary neurotrophic factor induces genes associated with inflammation and gliosis in the retina: a gene profiling study of flow-sorted, müller cells. PLoS ONE 2011 6 5 2-s2.0-79957564943 10.1371/journal.pone.0020326 e20326
83. Zhang K., Hopkins J. J., Heier J. S., Birch D. G., Halperin L. S., Albini T. A., Brown D. M., Jaffe G. J., Taoj W., Williams G. A., Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2011 108 15 6241 6245 2-s2.0-79955032437 10.1073/pnas.1018987108
84. Talcott K. E., Ratnam K., Sundquist S. M., Lucero A. S., Lujan B. J., Tao W., Porco T. C., Roorda A., Duncan J. L., Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Investigative Ophthalmology and Visual Science 2011 52 5 2219 2226 2-s2.0-79953134852 10.1167/iovs.10-6479